Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1290012 | 0.91 | BRD4 (0.35) | BRD4ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL19723581 | 0.89 | KDM4E (0.31) | NOTUMKDM4EALDH1A1GAAPKM | |
| SCHEMBL1290162 | 0.89 | NOTUM (0.37) | NOTUMKDM4EALDH1A1GAAPKM | |
| SCHEMBL1290198 | 0.88 | NOTUM (0.36) | NOTUMKDM4EALDH1A1GAAPKM | |
| SCHEMBL1290228 | 0.88 | KDM4E (0.34) | NOTUMKDM4EALDH1A1GAAPKM | |
| SCHEMBL1289976 | 0.87 | MCL1 (0.37) | BRD4NOTUMKDM4EALDH1A1GAA | |
| SCHEMBL4970983 | 0.87 | KDM4E (0.36) | NOTUMKDM4EALDH1A1GAAPKM | |
| SCHEMBL19712462 | 0.87 | BRD4 (0.35) | BRD4 | |
| SCHEMBL1289970 | 0.86 | NOTUM (0.40) | NOTUM | |
| SCHEMBL1290001 | 0.85 | BRD4 (0.36) | BRD4NOTUMKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10155021-B2 | Antimicrobial 4-oxoquinolizines | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2018-12-18 | — | — | US | claimed |
| EP-2670410-B1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EMERGENT PRODUCT DEV GAITHERSBURG INC (US) | 2017-12-20 | — | — | EP | claimed |
| US-20170232060-A9 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2017-08-17 | — | — | US | claimed |
| US-20170106045-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2017-04-20 | — | — | US | claimed |
| US-20150141435-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2015-05-21 | — | — | US | claimed |
| US-20130245035-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2013-09-19 | — | — | US | claimed |
| EP-2621491-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | Evolva SA (CH) | 2013-08-07 | — | — | EP | claimed |
| WO-2012047487-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2012-04-12 | — | — | WO | claimed |
| EP-3476844-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | Emergent Product Development Gaithersburg Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-3476844-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | Emergent Product Development Gaithersburg Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190105367-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2019-04-11 | — | — | US | disclosed |
| US-20190105367-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2019-04-11 | — | — | US | disclosed |
| US-10155021-B2 | Antimicrobial 4-oxoquinolizines | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2018-12-18 | — | — | US | disclosed |
| US-20180296555-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2018-10-18 | — | — | US | disclosed |
| US-20130245035-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2013-09-19 | — | — | US | disclosed |
| US-20130245035-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2013-09-19 | — | — | US | disclosed |
| EP-2621491-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | Evolva SA (CH) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012104305-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EVOLVA SA (CH) | 2012-08-09 | — | — | WO | disclosed |
| WO-2012047487-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012047487-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105367-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | BRD4 334/4885NOTUM 3732/4885LDHA 1956/4885 |
| US-10155021-B2 | Antimicrobial 4-oxoquinolizines | DCAF15, CUL4A, CUL4B | BRD4 333/4885NOTUM 3793/4885LDHA 2010/4885 |
| US-20180296555-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | TOP2A, TOP1, TOP2B | BRD4 1356/4885NOTUM 4787/4885LDHA 1828/4885 |
| US-20170106045-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | BRD4 334/4885NOTUM 3732/4885LDHA 1956/4885 |
| US-20170232060-A9 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | BRD4 334/4885NOTUM 3732/4885LDHA 1956/4885 |
| US-20150141435-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | TOP2A, TOP1, TOP2B | BRD4 1356/4885NOTUM 4787/4885LDHA 1828/4885 |
| US-20130245035-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | TOP2A, TOP1, TOP2B | BRD4 1153/4885NOTUM 4829/4885LDHA 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.